1 Study Coverage
1.1 Drugs for Non-Small Cell Lung Cancer Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million) Introduction
1.2 Global Drugs for Non-Small Cell Lung Cancer Outlook 2017 VS 2022 VS 2028
1.2.1 Global Drugs for Non-Small Cell Lung Cancer Market Size for the Year 2017-2028
1.2.2 Global Drugs for Non-Small Cell Lung Cancer Market Size for the Year 2017-2028
1.3 Drugs for Non-Small Cell Lung Cancer Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Drugs for Non-Small Cell Lung Cancer in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Drugs for Non-Small Cell Lung Cancer Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Drugs for Non-Small Cell Lung Cancer Market Dynamics
1.4.1 Drugs for Non-Small Cell Lung Cancer Industry Trends
1.4.2 Drugs for Non-Small Cell Lung Cancer Market Drivers
1.4.3 Drugs for Non-Small Cell Lung Cancer Market Challenges
1.4.4 Drugs for Non-Small Cell Lung Cancer Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Drugs for Non-Small Cell Lung Cancer by Type
2.1 Drugs for Non-Small Cell Lung Cancer Market Segment by Type
2.1.1 Radiofrequency Ablation (RFA)
2.1.2 Radiation Therapy
2.1.3 Chemotherapy
2.1.4 Targeted Therapies
2.1.5 Immunotherapy
2.2 Global Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017, 2022 & 2028)
2.3 Global Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017-2028)
2.4 United States Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017, 2022 & 2028)
2.5 United States Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017-2028)
3 Drugs for Non-Small Cell Lung Cancer by Application
3.1 Drugs for Non-Small Cell Lung Cancer Market Segment by Application
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Other
3.2 Global Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017, 2022 & 2028)
3.3 Global Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017-2028)
3.4 United States Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017, 2022 & 2028)
3.5 United States Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017-2028)
4 Global Drugs for Non-Small Cell Lung Cancer Competitor Landscape by Company
4.1 Global Drugs for Non-Small Cell Lung Cancer Market Size by Company
4.1.1 Top Global Drugs for Non-Small Cell Lung Cancer Companies Ranked by Revenue (2021)
4.1.2 Global Drugs for Non-Small Cell Lung Cancer Revenue by Player (2017-2022)
4.2 Global Drugs for Non-Small Cell Lung Cancer Concentration Ratio (CR)
4.2.1 Drugs for Non-Small Cell Lung Cancer Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Drugs for Non-Small Cell Lung Cancer in 2021
4.2.3 Global Drugs for Non-Small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Drugs for Non-Small Cell Lung Cancer Headquarters, Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million) Type
4.3.1 Global Drugs for Non-Small Cell Lung Cancer Headquarters and Area Served
4.3.2 Global Drugs for Non-Small Cell Lung Cancer Companies Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Drugs for Non-Small Cell Lung Cancer Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Drugs for Non-Small Cell Lung Cancer Market Size by Company
4.5.1 Top Drugs for Non-Small Cell Lung Cancer Players in United States, Ranked by Revenue (2021)
4.5.2 United States Drugs for Non-Small Cell Lung Cancer Revenue by Players (2020, 2021 & 2022)
5 Global Drugs for Non-Small Cell Lung Cancer Market Size by Region
5.1 Global Drugs for Non-Small Cell Lung Cancer Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Drugs for Non-Small Cell Lung Cancer Market Size by Region (2017-2028)
5.2.1 Global Drugs for Non-Small Cell Lung Cancer Market Size by Region: 2017-2022
5.2.2 Global Drugs for Non-Small Cell Lung Cancer Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth 2017-2028
6.1.2 North America Drugs for Non-Small Cell Lung Cancer Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth 2017-2028
6.3.2 Europe Drugs for Non-Small Cell Lung Cancer Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth 2017-2028
6.4.2 Latin America Drugs for Non-Small Cell Lung Cancer Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Drugs for Non-Small Cell Lung Cancer Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1 Bristol-Myers Squibb
7.1.1 Bristol-Myers Squibb Company Details
7.1.2 Bristol-Myers Squibb Business Overview
7.1.3 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Introduction
7.1.4 Bristol-Myers Squibb Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.1.5 Bristol-Myers Squibb Recent Development
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Company Details
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Introduction
7.2.4 GlaxoSmithKline Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.2.5 GlaxoSmithKline Recent Development
7.3 Menarini
7.3.1 Menarini Company Details
7.3.2 Menarini Business Overview
7.3.3 Menarini Drugs for Non-Small Cell Lung Cancer Introduction
7.3.4 Menarini Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.3.5 Menarini Recent Development
7.4 Sanofi
7.4.1 Sanofi Company Details
7.4.2 Sanofi Business Overview
7.4.3 Sanofi Drugs for Non-Small Cell Lung Cancer Introduction
7.4.4 Sanofi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.4.5 Sanofi Recent Development
7.5 Ziopharm Oncology
7.5.1 Ziopharm Oncology Company Details
7.5.2 Ziopharm Oncology Business Overview
7.5.3 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Introduction
7.5.4 Ziopharm Oncology Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.5.5 Ziopharm Oncology Recent Development
7.6 Alchemia
7.6.1 Alchemia Company Details
7.6.2 Alchemia Business Overview
7.6.3 Alchemia Drugs for Non-Small Cell Lung Cancer Introduction
7.6.4 Alchemia Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.6.5 Alchemia Recent Development
7.7 Amgen
7.7.1 Amgen Company Details
7.7.2 Amgen Business Overview
7.7.3 Amgen Drugs for Non-Small Cell Lung Cancer Introduction
7.7.4 Amgen Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.7.5 Amgen Recent Development
7.8 Apotex
7.8.1 Apotex Company Details
7.8.2 Apotex Business Overview
7.8.3 Apotex Drugs for Non-Small Cell Lung Cancer Introduction
7.8.4 Apotex Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.8.5 Apotex Recent Development
7.9 BioMarin Pharmaceutical
7.9.1 BioMarin Pharmaceutical Company Details
7.9.2 BioMarin Pharmaceutical Business Overview
7.9.3 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Introduction
7.9.4 BioMarin Pharmaceutical Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.9.5 BioMarin Pharmaceutical Recent Development
7.10 CellAct Pharma
7.10.1 CellAct Pharma Company Details
7.10.2 CellAct Pharma Business Overview
7.10.3 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Introduction
7.10.4 CellAct Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.10.5 CellAct Pharma Recent Development
7.11 Cerulean Pharma
7.11.1 Cerulean Pharma Company Details
7.11.2 Cerulean Pharma Business Overview
7.11.3 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Introduction
7.11.4 Cerulean Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.11.5 Cerulean Pharma Recent Development
7.12 Cipla
7.12.1 Cipla Company Details
7.12.2 Cipla Business Overview
7.12.3 Cipla Drugs for Non-Small Cell Lung Cancer Introduction
7.12.4 Cipla Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.12.5 Cipla Recent Development
7.13 Cornerstone Pharmaceuticals
7.13.1 Cornerstone Pharmaceuticals Company Details
7.13.2 Cornerstone Pharmaceuticals Business Overview
7.13.3 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
7.13.4 Cornerstone Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.13.5 Cornerstone Pharmaceuticals Recent Development
7.14 Curis
7.14.1 Curis Company Details
7.14.2 Curis Business Overview
7.14.3 Curis Drugs for Non-Small Cell Lung Cancer Introduction
7.14.4 Curis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.14.5 Curis Recent Development
7.15 CytRx
7.15.1 CytRx Company Details
7.15.2 CytRx Business Overview
7.15.3 CytRx Drugs for Non-Small Cell Lung Cancer Introduction
7.15.4 CytRx Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.15.5 CytRx Recent Development
7.16 Eli Lilly
7.16.1 Eli Lilly Company Details
7.16.2 Eli Lilly Business Overview
7.16.3 Eli Lilly Drugs for Non-Small Cell Lung Cancer Introduction
7.16.4 Eli Lilly Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.16.5 Eli Lilly Recent Development
7.17 Exelixis
7.17.1 Exelixis Company Details
7.17.2 Exelixis Business Overview
7.17.3 Exelixis Drugs for Non-Small Cell Lung Cancer Introduction
7.17.4 Exelixis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.17.5 Exelixis Recent Development
7.18 Fresenius Kabi
7.18.1 Fresenius Kabi Company Details
7.18.2 Fresenius Kabi Business Overview
7.18.3 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Introduction
7.18.4 Fresenius Kabi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.18.5 Fresenius Kabi Recent Development
7.19 Genentech
7.19.1 Genentech Company Details
7.19.2 Genentech Business Overview
7.19.3 Genentech Drugs for Non-Small Cell Lung Cancer Introduction
7.19.4 Genentech Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.19.5 Genentech Recent Development
7.20 Hikma Pharmaceuticals
7.20.1 Hikma Pharmaceuticals Company Details
7.20.2 Hikma Pharmaceuticals Business Overview
7.20.3 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
7.20.4 Hikma Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.20.5 Hikma Pharmaceuticals Recent Development
7.21 Hospira
7.21.1 Hospira Company Details
7.21.2 Hospira Business Overview
7.21.3 Hospira Drugs for Non-Small Cell Lung Cancer Introduction
7.21.4 Hospira Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.21.5 Hospira Recent Development
7.22 Intas Pharmaceuticals
7.22.1 Intas Pharmaceuticals Company Details
7.22.2 Intas Pharmaceuticals Business Overview
7.22.3 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
7.22.4 Intas Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.22.5 Intas Pharmaceuticals Recent Development
7.23 Karyopharm Therapeutics
7.23.1 Karyopharm Therapeutics Company Details
7.23.2 Karyopharm Therapeutics Business Overview
7.23.3 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Introduction
7.23.4 Karyopharm Therapeutics Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.23.5 Karyopharm Therapeutics Recent Development
7.24 Kyowa Hakko Kirin
7.24.1 Kyowa Hakko Kirin Company Details
7.24.2 Kyowa Hakko Kirin Business Overview
7.24.3 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Introduction
7.24.4 Kyowa Hakko Kirin Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.24.5 Kyowa Hakko Kirin Recent Development
7.25 Ligand Pharmaceuticals
7.25.1 Ligand Pharmaceuticals Company Details
7.25.2 Ligand Pharmaceuticals Business Overview
7.25.3 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
7.25.4 Ligand Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
7.25.5 Ligand Pharmaceuticals Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
